Integral Derivatives’s Zimmer Biomet ZBH Stock Holding History

Integral Derivatives’s Portfolio ZBH Stock Details ZBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-3,068	Closed	-$280K	–	1257
2015 Q3	$280K	Sell	3,068 -1,236	-29%	-$124K	0.01%	878
2015 Q2	$456K	Sell	4,304 -974	-18%	-$108K	0.01%	748
2015 Q1	$602K	Buy	5,278 +2,987	+130%	+$341K	0.01%	651
2014 Q4	$252K	Sell	2,291 -4,017	-64%	-$423K	﹤0.01%	1151
2014 Q3	$616K	Buy	+6,308	New	+$620K	0.01%	904

Other funds holding ZBH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Longview Partners St Peter Port, Guernsey $6.16B AUM 3.55% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Integral Derivatives's ZBH Position: Q4 2015 in Review

Integral Derivatives sold out of Zimmer Biomet (ZBH) in Q4 2015, closing a stake of 3,068 shares — an estimated $280K sold.

Integral Derivatives first reported a position in ZBH in Q3 2014 and held it in 5 quarters. The position peaked at $616K in Q3 2014. 740 funds tracked by Wall St. Rank hold ZBH as of Q4 2015.

Integral Derivatives reported no remaining Zimmer Biomet position as of Q4 2015 after selling out during the quarter.
Integral Derivatives sold 3,068 Zimmer Biomet shares in Q4 2015, an estimated $280K.
Integral Derivatives first reported a position in Zimmer Biomet in Q3 2014 and held it in 5 quarters.
Integral Derivatives's Zimmer Biomet position peaked at $616K in Q3 2014.
740 funds tracked by Wall St. Rank held Zimmer Biomet as of Q4 2015.

Based on Integral Derivatives's 13F filing for Q4 2015, filed 22 Jan 2016.